Emulate, Inc., a Cambridge, MA-based developer of a range of applications in drug development, personalized medicine, agriculture and chemical-based consumer products, raised $12m in Series A financing.
The round was led by NanoDimension, with participation from Cedars-Sinai Medical Center and private investor Hansjörg Wyss.
The company intends to use the funds to advance the first commercial applications of its platform through co-innovation with corporate and clinical clients, and through internal development programs.
Its initial focus will be use of Organs-on-Chips to provide accurate evaluation of human responses to drugs and cosmetics, and to create new clinical guidance tools for personalized therapies.
Led by James Coon, Chief Executive Officer, Emulate aims to commercialize its Organs-on-Chips bioemulation products, automated platform and software to enhance innovation and accelerate the development of pharmaceutical, chemical, cosmetic, and personalized medicine products. It focuses on commercializing Organs-on-Chips as an automated human bioemulation platform for mimicking true human physiology so that responses to medicines, chemicals and diseases can be accurately predicted.